ANUHPHRPharmaceuticals
Anuh Pharma Ltd — Profit & Loss Statement
₹67.00
-2.77%
Anuh Pharma Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | 1.47 Cr | 2.45 Cr | 1.04 Cr | 0.59 Cr |
| Tax Rate For Calcs | 0.22 | 0.23 | 0.24 | 0.22 |
| Normalized EBITDA | 63.78 Cr | 76.74 Cr | 53.04 Cr | 49.34 Cr |
| Total Unusual Items | 6.58 Cr | 10.51 Cr | 4.35 Cr | 2.70 Cr |
| Total Unusual Items Excluding Goodwill | 6.58 Cr | 10.51 Cr | 4.35 Cr | 2.70 Cr |
| Net Income From Continuing Operation Net Minority Interest | 47.35 Cr | 60.06 Cr | 36.18 Cr | 30.56 Cr |
| Reconciled Depreciation | 8.74 Cr | 8.58 Cr | 9.70 Cr | 11.96 Cr |
| Reconciled Cost Of Revenue | 499.37 Cr | 486.66 Cr | 401.48 Cr | 377.68 Cr |
| EBITDA | 70.36 Cr | 87.25 Cr | 57.39 Cr | 52.04 Cr |
| EBIT | 61.62 Cr | 78.66 Cr | 47.69 Cr | 40.08 Cr |
| Net Interest Income | 0.19 Cr | 0.22 Cr | -0.30 Cr | -0.54 Cr |
| Interest Expense | 0.62 Cr | 0.35 Cr | 0.22 Cr | 0.96 Cr |
| Interest Income | 1.44 Cr | 1.17 Cr | 0.45 Cr | 1.04 Cr |
| Normalized Income | 42.24 Cr | 52.00 Cr | 32.86 Cr | 28.45 Cr |
| Net Income From Continuing And Discontinued Operation | 47.35 Cr | 60.06 Cr | 36.18 Cr | 30.56 Cr |
| Total Expenses | 604.67 Cr | 579.34 Cr | 483.04 Cr | 449.44 Cr |
| Rent Expense Supplemental | 0.48 Cr | 0.40 Cr | 0.38 Cr | 0.38 Cr |
| Diluted Average Shares | 10.02 Cr | 10.02 Cr | 10.02 Cr | 10.02 Cr |
| Basic Average Shares | 10.02 Cr | 10.02 Cr | 10.02 Cr | 10.02 Cr |
| Diluted EPS | 4.72 | 5.99 | 3.61 | 3.05 |
| Basic EPS | 4.72 | 5.99 | 3.61 | 3.05 |
| Diluted NI Availto Com Stockholders | 47.35 Cr | 60.06 Cr | 36.18 Cr | 30.56 Cr |
| Net Income Common Stockholders | 47.35 Cr | 60.06 Cr | 36.18 Cr | 30.56 Cr |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 47.35 Cr | 60.06 Cr | 36.18 Cr | 30.56 Cr |
| Net Income Including Noncontrolling Interests | 47.35 Cr | 60.06 Cr | 36.18 Cr | 30.56 Cr |
| Net Income Continuous Operations | 47.35 Cr | 60.06 Cr | 36.18 Cr | 30.56 Cr |
| Tax Provision | 13.65 Cr | 18.25 Cr | 11.29 Cr | 8.56 Cr |
| Pretax Income | 61.01 Cr | 78.31 Cr | 47.47 Cr | 39.12 Cr |
| Other Non Operating Income Expenses | 0.13 Cr | 0.11 Cr | 0.06 Cr | 0.05 Cr |
| Special Income Charges | -1.25 Cr | -0.21 Cr | 0.01 Cr | 0.06 Cr |
| Other Special Charges | -0.02 Cr | 0.02 Cr | -0.01 Cr | -0.06 Cr |
| Write Off | 1.27 Cr | 0.19 Cr | 0.00 | 0.00 |
| Net Non Operating Interest Income Expense | 0.19 Cr | 0.22 Cr | -0.30 Cr | -0.54 Cr |
| Total Other Finance Cost | 0.62 Cr | 0.60 Cr | 0.53 Cr | 0.62 Cr |
| Interest Expense Non Operating | 0.62 Cr | 0.35 Cr | 0.22 Cr | 0.96 Cr |
| Interest Income Non Operating | 1.44 Cr | 1.17 Cr | 0.45 Cr | 1.04 Cr |
| Operating Income | 56.84 Cr | 67.67 Cr | 44.45 Cr | 37.20 Cr |
| Operating Expense | 105.31 Cr | 92.68 Cr | 81.56 Cr | 71.76 Cr |
| Other Operating Expenses | 68.23 Cr | 60.47 Cr | 51.54 Cr | 41.99 Cr |
| Depreciation And Amortization In Income Statement | 8.74 Cr | 8.58 Cr | 9.70 Cr | 11.96 Cr |
| Depreciation Income Statement | 8.74 Cr | 8.58 Cr | 9.70 Cr | 11.96 Cr |
| Selling General And Administration | 4.40 Cr | 3.57 Cr | 2.55 Cr | 2.12 Cr |
| Selling And Marketing Expense | 1.84 Cr | 1.61 Cr | 1.08 Cr | 0.79 Cr |
| General And Administrative Expense | 2.56 Cr | 1.96 Cr | 1.47 Cr | 1.33 Cr |
| Rent And Landing Fees | 0.48 Cr | 0.40 Cr | 0.38 Cr | 0.38 Cr |
| Gross Profit | 162.15 Cr | 160.34 Cr | 126.00 Cr | 108.97 Cr |
| Cost Of Revenue | 499.37 Cr | 486.66 Cr | 401.48 Cr | 377.68 Cr |
| Total Revenue | 661.51 Cr | 647.00 Cr | 527.49 Cr | 486.65 Cr |
| Operating Revenue | 661.51 Cr | 647.00 Cr | 527.49 Cr | 486.65 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Anuh Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.